OnkoSight NGS MDS Panel

Synonyms

• LAB4140
• ONKOSIGHT NGS MDS PANEL

Cerner Name

OnkoSight Advanced NGS MDS Panel

Clinical Info

Tumor sequencing by NGS detecting mutations in 18 genes associated with MDS. Mutations often have prognostic significance, may confer resistance 
to FDA approved therapies, or may qualify patients for late-stage clinical trials.

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

Blood

Specimen Volume

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender top tube
Specimen: 2 mL Bone Marrow or Whole Blood
Alternate Specimens: Bone Marrow - Green Top, Peripheral Blood - Lavender Top,
Peripheral Blood - Green Top, Eppendorf tube, Unstained Slide, Formalin-fixed,
Paraffin-embedded tissue 
Decalcified specimens are not recommended for NGS testing
Note: Please indicate specimen type

Transport Instructions

Room Temperature

Specimen Stability

30 Days Room Temperature

Methodology

Genotyping by Next Generation Sequencing
Genes:
ASXL1; BCOR; CBL;DNMT3A; ETV6; EZH2
JAK2; KRAS; NRAS; PTPN11; RUNX1; SETBP1
SF3B1; SRSF2; TET2; TP53; U2AF1; ZRSR2

Days Performed

TAT 10 - 12 Days

Performing Laboratories

GenPath BioReference
Test Code: TL98

CPT

81450

PDM

1659926

Results

Result Interpretation

Forms